Pharma vs The IRA — Industry Leaders React To Merck Lawsuit
Execs offer a guarded reaction, noting the need for continued dialogue, but note the dire threat that the pricing program poses to the pharma business model.
Execs offer a guarded reaction, noting the need for continued dialogue, but note the dire threat that the pricing program poses to the pharma business model.